Aberrant expression of ETS1 and ETS2 proteins in cancer

The ETS transcription factors regulate expression of genes involved in normal cell development, proliferation, differentiation, angiogenesis, and apoptosis, consisting of 28 family members in humans. Dysregulation of these transcription factors facilitates cell proliferation in cancers, and several members participate in invasion and metastasis by activating gene transcription. ETS1 and ETS2 are the founding members of the ETS family and regulate transcription by binding to ETS sequences. They are both involved in oncogenesis and tumor suppression depending on the biological situations used. The essential roles of ETS proteins in human telomere maintenance have been suggested, which has been linked to creation of new Ets binding sites. Recently, preferential binding of ETS2 to gain-of-function mutant p53 and ETS1 to wild type p53 (WTp53) have been suggested, raising the tumor promoting role for the former and tumor suppressive role for the latter. The oncogenic and tumor suppressive functions of ETS1 and 2 proteins have been discussed. *Correspondence to: Kazushi Inoue, Department of Pathology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA, Tel: 13364071642; Fax: 13367652486; E-mail: kinoue2@triad.rr.com


Introduction
The oncogene v-ets was originally discovered as a component of a chimeric gene along with a truncated v-myb gene, present in the genome of E26, an avian leukosis virus ( Figure 1A) [1][2][3]. Members of the ETS gene family have been cloned and sequenced from a variety of species ranging from human to Drosophila. Ets proteins are highly conserved through different species [4]. -binding protein alpha chain), ELF1/2/4, SPI1 (SPI1/B/C), TEL (ETV6/7), ERF (ERF, ETV3, ETV3L), FLI1 and FEV [4]. In addition, a subset of four ETS family genes (ELF3, ELF5, EHF, SPDEF) has been characterized as placenta-specific subgroup based upon their restricted expression to tissues with high epithelial cell content [4][5][6], totally 28 ETS proteins in humans.
The ETS transcriptions factors regulate numerous genes by binding to winged helix-turn-helix GGAA/T core of DNA-binding, and are involved in cell proliferation, differentiation, development, stem cell development, transformation, angiogenesis, and apoptosis [7][8][9][10][11][12][13]. ETS1 and ETS2 are representative members of the ETS family of transcription factors and are downstream effectors of the RAS/RAF/ERK pathway [14][15][16][17][18][19] (Figure 2). The pointed domain is at the N-terminal end (Figure 1, Pnt-P2 and Yan domain [PNT] in [20]). Overexpression of dominant-negative forms of several ETS factors, including ETS1 or ETS2, block Ras transformation [16,21,22] suggesting that ETS family members play a crucial role in this process. However, specific deletions of ETS family members are more accurate approaches for the understanding of functions of ETS members in Ras transformation [23]. It has been reported that aberrant activation of the ETS family transcription factors play roles throughout all stages of tumorigenesis [24]. Specifically in solid tumors, gene rearrangement/ amplification, feed-forward growth factor signaling loop, formation of gain-of-function co-regulatory complexes, and novel cis-acting mutations in ETS target gene promoters can result in increased ETS activity [24]. The ETS signaling enhances tumorigenesis through different mechanisms such as lineage specification, increased selfrenewal, and genomic instability confirming the proto-oncogenic roles of ETS proteins in cancer.
It was reported that that the ETS2 gene was located about 17 cM from the breakpoint of common t(8;21) translocation found in acute myelogenous leukemia (AML) [25,26], esp. M2 subclass. Then the chimeric gene at t(8;21) translocation was AML1-ETO was cloned and characterized [27,28]. Although the chimeric gene responsible for acute myeloid leukemia was did not contain ETS, the ETS family ERG1 was situated just proximal to ETS2 at 21q22.3 [29,30] ( Figure 1B). They found that the ERG1 gene was translocated from chromosome 21 to chromosome 8 in the t(8;21)(q22;q22) [30]. The ERG protein was considerably more stable than the short-lived ETS1 and ETS2 proteins with a half-life of 21 hours. It was then reported that ERG2 is a nuclear phosphoprotein bound to purine-rich sequences [31]. The ERG2 protein was a sequence-specific, DNA-binding protein and is expressed at higher levels in early myeloid cells than in mature lymphoid cells, acting as a regulator of genes required for maintenance and differentiation of early hematopoietic cells [31].
Human telomerase reverse transcriptase gene (TERT) encodes a rate-limiting catalytic subunit of telomerase essential for genomic integrity [11,[32][33][34]. TERT expression is repressed in somatic cells except for self-renewing proliferative cells and tumor cells [32]. Thus, immortality associated with cancer cells has been thought to be caused by telomerase overexpression. Importantly, the newly described germline and recurrent somatic mutations in melanoma [35] and other cancers [36] in the TERT promoter that create de novo ETS/   [178,179], enhanced DNA binding of nuclear proteins [180,181], recruitment of co-repressors [182,183], and gene transactivation [184,185] involved in cell proliferation, apoptosis, angiogenesis. Mutation of hTERT promoter created novel ETS binding sites, which contributes increased telomerase activity in cancer cells. Mutant p53 which is overexpressed in half of human cancer cells, bind to ETS2 to stabilize the protein and reveal its oncogenic activity.
TCF binding sites, provide an insight into the possible cause of tumorspecific increased TERT expression [32,33,37].
Most mutant p53 (mtp53) expressed in cancer cells has gainof-function (GOF) associated with genomic instability, increased tumorigenicity and stem cell-ness, invasiveness/metastasis, and resistance to chemo/radiation therapy [ [38,44,46]. Preferential binding of ETS1 to WTp53 and ETS2 to mtp53 have been reported, suggesting tumor-suppressive function for the former and oncogenic function for the latter, which is discussed in this review.
In 2005, Zhan, et al. reported significantly reduced arterial wall thickening, perivascular fibrosis, and cardiac hypertrophy Ets1deficient mice in response to angiotensin II [62]. The induction of two known targets of ETS1, CDKN1a (p21 CIP1 ) and Plasminogen Activator 1, by angiotensin II was markedly decreased in the aorta of Ets1-null mice compared with wild types [62]. The expression of Monocyte Chemotactic Protein 1 was also reduced, resulting in significantly diminished recruitment of T cells and macrophages to vessel walls. They concluded that ETS1 has an essential role as a transcriptional mediator of vascular inflammation and remodeling in response to angiotensin II [62].

Mice model for Ets2 overexpression and deficiency
Expression of ETS2 is observed in a variety of cell types. During murine development, it is highly expressed in newly forming cartilage including skull precursor cells, and vertebral primordia [74]. Sumarsono, et al. created transgenic mice to investigate the consequences of overexpression of Ets2 [74]. The mice with less than 2-fold Ets2 overexpression in particular organs developed neurocranial, visceral cranial, and cervical skeletal abnormalities [74]. Of note, these abnormalities had similarities with those found in trisomy 16 humans with Down's syndrome, in which the gene dosage of ETS2 was increased. Thus, ETS2 has a role in skeletal development and that overexpression is contributed skeletal abnormalities found in Down's syndrome [75]. This is a nice study that link ETS2 with human disease.
They also reported that overexpression of ETS2 resulted in apoptosis [75]. Transgenic mice overexpressing ETS2 developed a smaller thymus and lymphocyte abnormalities, similar to features observed The ETS gene often fuses with others as a result of translocation. For instance, ETS1 is found in breakpoints such as t(9;11)(p22;q23) and t(4;11)(q21;q23) that are often found in human leukemias [47,48]. It is often overexpressed in human cancer with Cyclin D1 [49], p16 INK4a [50] and telomerase [51] overexpression, and thus is heavily involved in human carcinogenesis). Human chromosomal translocations involving ETS family genes have been amply reported on ERG:FUS (acute leukemia), EWS:FLI1 (Ewing sarcoma), ERG:TMPRSS2 (prostate cancer), which will be reviewed in a different paper since Ets is such a big family. Here we will focus on Ets1 and Ets2 in carcinogenesis.

Ets1 and Ets2
Gene cloning and the protein structure Watson et al. cloned and sequenced ETS1 and ETS2 cDNA clones obtained from human and mouse [52] ( Figure 1B). In mammals, the Ets sequences are located on two separate chromosomal loci, called Ets1 and Ets2. To determine the structure and open reading frames of these two genes, they sequenced human Ets1 and Ets2 cDNA clones obtained from both human and mouse. The human ETS1 gene encodes a protein of 441 amino acids. This protein is greater than 95% identical to the chicken c-Ets1 gene product. Thus, the human ETS1 gene is homologous to the chicken c-Ets1 gene, the proto-oncogene that the E26 virus. Human and mouse Ets2 cDNA clones are closely related to Ets1 having open reading frames for proteins of 469 and 468 residues, respectively. By in situ hybridization, de Taisne Figure 1A).
The ETS1 and ETS2 genes are located on the same chromosome and are coordinately transcribed in avians [54]. Whereas the chicken Ets protein distributes equally between the cytoplasm and nucleus, the human ETS1 protein is cytoplasmic while the ETS2 protein is nuclear suggesting that they have different biologic functions [55]. ETS1 is a 441-amino acid protein that contains an N-terminal domain with PNT implicated in the self-association of oncoproteins and a C-terminal DNA-binding domain ( Figure 1B). Of note, it has a MAPK phosphorylation site at Thr38 that mediates transcriptional regulation [56]. Splice variants of ETS1 has been characterized: the full-length ETS1 encodes a 51-kD protein (ETS1-p51) while ETS1∆VII lacks exon 7 and encodes ETS1-p42 [57]. The latter lacks the N-terminal inhibitory domain found in ETS1-p51, but has unique DNA-binding and transcriptional properties and regulates different target genes [57]. Laitem, et al. identified a novel variant of Ets1∆(III-VI), resulting from the alternative splicing of exons III to VI encoding a 27 kDa isoform [57]. Ets1-p27 lacks the Thr38 residue, PNT, and the transactivation domain, all of which are required for the transactivation by Ets1. They also showed that Ets1-p27 binds DNA in the same way as Ets1-p51 does and induces the translocation of Ets1-p51 from the nucleus to the cytoplasm thereby constituting a dominant-negative of Ets1-p51 [57].
[54] mapped the ETS2 gene to chromosome 21q22.1-q22.3 by in situ hybridization. Mavrothalassitis [58] reported that the ETS2 gene has no TATA box or CAAT box in its promoter. Then Owczarek et al. determined that the ETS2 gene spans 17.6 kb and has a major CpG island at its 5' untranslated region [59]. The product, ETS2 protein consists of 469 amino acids with an N-terminal pointed domain and a C-terminal DNA-binding domain [60] ( Figure 1B). It also has a MAPK phosphorylation site at Thr72 that likely mediates transcriptional regulation. In short, the structure for ETS1 and ETS2 is very similar ( Figure 1B). in Down's syndrome. Importantly, increased apoptosis correlated with increased expression of p53, and alterations in downstream targets in the p53 pathway [75] suggesting that ETS2 stimulates p53. In HeLa cells, transfection with wild type (WT) p53 enabled ETS2 overexpression to induce apoptosis suggesting crosstalks between ETS2 and p53. Furthermore, crossing the ETS2-transgenic mice with p53 -/mice rescued the thymic apoptosis phenotype [75]. These are extremely important findings in vivo since Ets2 binds to mtp53 and is an essential transcription factor for mtp53 to revel its oncogenic activity (explained later in detail). In conclusion, overexpression of ETS2 induces apoptosis dependent on p53.
Inactivation of Ets2 in mice by deletion of the Ets domain (Ets2 db1 ) caused embryonic lethality before E8.5 [76]. Analysis of the mutant Ets2 db1/db1 conceptuses (products of conception) revealed deficiencies in trophoblastic tissues, including a smaller ectoplacental cone and absence of chorion formation. Further analysis has revealed that many Ets2 db1/db1 conceptuses fail to form extraembryonic ectoderm [77]. Then Wen, et al. [78] created an Ets2 conditional knockout allele (Ets2 flox ) in mice. An epiblast-specific Cre line, Mox2-Cre, was crossed with Ets2 flox/ wt mice to delete Ets2 in germ and embryonic cells [79]. However, the resulting recombined allele designated Ets2 db2 , caused recessive embryonic lethality around E8 when bred to homozygosity. Ets2 db2/db2 embryos at E7.5 were very similar to the Ets2 db1/db1 mutants [76] with much smaller conceptuses and unusual cone-shaped yolk sacs. They showed that inactivation of Ets2 resulted in trophoblast stem (TS) cell slower growth, increased expression of differentiation-associated genes, and decreased expression of genes implicated in TS self-renewal [77].
In conclusion, Ets2 contributes to the regulation of genes important for maintaining the undifferentiated state of TS cells and is essential for embryonic development [78,79].

The ETS1 gene function in tumorigenesis
Using two different highly tumorigenic human colon cancer cell lines DLD-1 and HCT116 that do not express endogenous ETS1 protein, Suzuki, et al. [80] found that ETS1 reversed the transformed phenotype in a dose-dependent fashion, indicating its tumorsuppressive potential [80]. The result is very important since Ets1 bind to WT p53 for tumor suppression (mentioned later in this review). It is a good model for studying suppression of tumorigenicity by ETS1 at transcriptional level, leading to the design and development of novel drugs for cancer therapy [80].
Hashiya et al. expressed human ETS1 into rat hindlimb and found that it stimulated angiogenesis, as measured by increased capillary density and blood flow [81]. Overexpression of ETS1 upregulated the concentrations of hepatocyte growth factor and vascular endothelial growth factor in rat hindlimb. Their study demonstrated that ETS1 regulated angiogenesis through the induction of angiogenic growth factors. Blocking ETS1 expression may thus provide a new therapeutic strategy to treat peripheral arterial disease [81,82].

Alteration of ETS1 in human cancer
The ETS family of transcription factors regulates the expression of genes involved in normal cell development, proliferation, and differentiation [4][5][6][83][84][85]. Therefore, the dysregulation of these transcription factors facilitates cell proliferation in many cancers, and several ETS members have been shown to participate in invasion and metastasis by activating gene transcription [83][84][85]. In three patients with acute monocytic leukemia (AMoL) and t(9;11)(p22;q23) showed that the breakpoint on 9p split the interferon genes and that the Interferon β1 gene was translocated to chromosome 11 [86]. As a consequence, the ETS1 gene was translocated from chromosome 11 to 9p adjacent to interferon genes. They suggested that juxtaposition of interferon and ETS1 genes might be involved in the pathogenesis of AMoL [86].
ETS1 overexpression is also found in human breast cancer (BC) associated with invasiveness and poor prognosis [87,88]. By overexpressing Ets1 or a dominant-negative mutant in BC cells, it was shown that ETS1 plays a key role in coordinating multiple invasive features of cancer cells [87]. They noticed that ETS1 decreased the density of BC cells cultured in three-dimensional extracellular matrix gels. ETS1 overexpression was deleterious to anchorage-independent growth of cells in soft agar. The role of ETS1 was confirmed in vivo, during primary tumor growth and metastatic assay of lung colonization [87] associated with epithelial-to-mesenchymal transition features [89] and high Ki67 [90] -positive cells. siRNA-mediated knockdown of ETS1 in human BC cell lines decreased colony growth, both in anchorage-independent assays and 3D extracellular matrix cultures. These observations suggested an oncogenic role of ETS1 in breast tumorigenesis [87]. In contrast to ETS1, loss of the Myb-like transcription factor DMP1α (DMTF1α) binds to the Ets site in the Arf promoter [91] is associated with low Ki67 and is associated with favorable prognosis [92] for Dmp1 [93-101; 67, 102-106 for reviews]. Dmp1α also binds directly to p53 for activation in Arf-deficient cells [100,101]. It was reported that expression of neuNT, but not normal neu, caused transcriptional activation of Ets, AP1, or NF-κB-dependent reporter genes [107]. Co-transfection of dominant inhibitory Ets2 mutants specifically blocked neuNT-mediated activation of Etsdependent reporter genes [107]. Thus, Ets activation is required for neuNT-mediated cellular transformation [105,[108][109][110].
Previous reports have demonstrated that ETS1 is required for activation of the RAS/ERK pathway and migration of RAS/ERKactivated cells by transcriptional activation through ETS/AP1 sites [111,112]. In invasive BC, upregulation of ETS1 was associated with high aggressiveness and poor prognosis. Consistent with this observation, ETS1 regulates the expression of important angiogenetic and extracellular matrix remodeling factors such as VEGF, matrix metalloproteinases [113,114]. Furthermore, ETS1 represses genes such as DUSP4, DUSP6, and SPRY4, all of which provide negative feedback to the RAS/ERK pathway [85]. Statins, small molecule inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR), exert anti-tumor effects by altering the RAS/RAF/EK/ERK and RAS/ PIK3CA/AKT signaling pathways [115,116]. Lipophilic statins inhibit the growth and proliferation of BC cells, especially hormone receptornegative, basal-like BC cells [117][118][119][120]. Based on these studies, Jung et al. hypothesized that statins suppress TNBC growth by altering the expression of DUSP4 and ETS1 [121]. They demonstrated that ETS1 mRNA and protein were overexpressed in TNBC cells compared with other BC cell lines, where DUSP4 mRNA was downregulated. In addition, simvastatin restored Dusp4-deficiency and suppressed ETS1 expression in TNBC. Moreover, they found that depletion of DUSP4 overcame the anti-tumor activity of statins. MAPK pathway inhibitor, U0126 and PI3KCA inhibitor LY294002 also decreased levels of Ets1, phosphor-ERK and phosphor-AKT on Western blot assays. Taken together, these studies suggest the oncogenic function of Ets1 in cancer, and simvastatin potentially affects the activity of transcriptional factors such as ETS1 and DUSP4 through the MAPK pathway [121]. If ETS1 is a critical mediator for the RAS/MEK/ERK signaling, it could act as a tumor promoter or repressor dependent on the biological condition   [122][123][124][125] because excessive stimulation of this pathway result in Arf-p53 dependent senescence.

Expression of ETS2 in human cancer: influences on Cyclin D1 and p16 INK4a expression
One important function of ETS2 is the Cyclin D1 promoter regulation [49,126]. Cyclin D1, the regulatory subunit of several cyclin-dependent kinases (CDK2/4/6), is required for, and capable of shortening, the G1 phase of the cell cycle [127,128]. The transforming mutants of p21 Ras  The p16 INK4a cyclin-dependent kinase inhibitor (CDKN2a) has been implicated in replicative senescence, the state of permanent growth arrest driven by cell divisions or constitutive Ras-Raf-MEK signaling [131][132][133][134] (Figure 2). The p16 INK4a cyclin-dependent kinase inhibitor is implicated in replicative senescence, the state of permanent growth arrest caused by cumulative cell divisions or constitutive Ras-Raf-MEK signaling [50]. p16 INK4a is an essential tumor suppressor that prevents the emergence of incipient cancer cells [134]. The gene expression is regulated at the transcription level and thus the promoter analysis is critical [135,136]. Regulation of p16 INK4a expression occurs at the transcriptional level, and involves epigenetic control and multiple transcription factors. PRC1 (Pombe repressor complex 1) and PRC2 (Pombe repressor complex 2) proteins, and histone deacetylases play an important role in the promoter hypermethylation for suppressing p16 INK4a expression by YY1 [137] and Id1 [138]. Ohtani, et al. The tumor suppressor PTEN has both lipid and protein phosphatase activities [139][140][141]. Its lipid phosphatase activity is essential for its tumor-suppressive function via the phosphoinositide 3-kinase (PI3K) and AKT1 pathways. Weng et al. showed that overexpression of wild type PTEN in the MCF7 breast cancer cells resulted in a phosphatase activity-dependent decrease in the phosphorylation of ETS2 [142]. Interestingly, exposure of MCF7 cells to insulin, insulin-like growth factor-1, or epidermal growth factor lead to the phosphorylation of ETS2. They also reported that the MAP2K1 inhibitor PD590089 cancelled insulin-stimulated phosphorylation of ETS2 [142]. Overexpression of PTEN abrogated activation of the Ras-responsive enhancer, a target of ETS2 action, in a phosphatase-dependent manner [142]. In short, PTEN blocks insulin-stimulated ETS2 phosphorylation through inhibition of the MAP kinase independently of PI3K, which may be mediated through PTEN's protein phosphatase activity [142].

ETS proteins in telomere maintenance
Telomere repeats at chromosomal ends, critical to genome integrity, are maintained through complicated network of proteins and pathways [11,32,33]. A specialized ribonucleic protein, telomerase, maintains telomere homeostasis through repeated addition to counter intrinsic shortcomings of DNA replication that leads to gradual sequence shortening (telomere erosion) in successive mitoses [143,144]. The telomerase is composed of telomerase reverse transcriptase (TERT) subunit and an RNA component [143]. Telomerase, while present in stem cells, is deactivated due to epigenetic silencing of the rate-limiting TERT upon differentiation in most of somatic cells [11]. However, in most cancer cells, telomerase reactivation remains a ubiquitous process and constitutes one of the major hallmarks [143][144][145]. Discovery of mutations within the core promoter of the TERT gene that create de novo binding sites for ETS transcription factors [32,33] provided a mechanism for cancer-specific telomerase reactivation [11] (Figures 2  and 3). In human cancers, the TERT promoter mutations have been shown to define subsets of patients with poor prognosis with increased transcription of TERT, telomerase reactivation, resulting in increased telomere length. Thus, the TERT promoter mutations have the potential for therapeutic target for cancer [11,32,33].
The Wilms' tumor 1 gene product, which can either be tumor suppressive [146] or oncogenic [147][148][149][150][151], can regulate hTERT gene expression and hence telomerase activity in cancer cells via multiple pathways [12] (Figure 3). It has been reported that WT1 directly bound to p53, and could be either transcriptional repressor or activator dependent on the status of p53 [152,153]. Thus it is likely that WT1 is a transactivator for hTERT rather than repressor in cancer stem cells where p53 in mutated. Indeed, most cases of leukemia show both the TERT and WT1 gene overexpression [154]. Consistently, the TERT and WT1 gene expression analyses provided useful pieces of information for the understanding of chronic myelogenous leukemia progression and their possible usefulness as surrogate markers for treatment monitoring [154].
Data from ChiP [99], Chip on Chip [169], and Chip-Seq [170] revealed that ~50% of promoters occupied by mtp53 contained ETSbinding sites, suggesting that physical binding with ETS proteins is an essential mechanism by which mtp53 regulates gene expression for oncogenic transformation [159,160]. Importantly, these mtp53bound genomic regions do not have a WTp53 response element 5′-PuPuPuC(A/T)(A/T)GPyPyPy-3 [171], indicating that the mtp53 proteins do not cause transformation through direct binding to DNA [159]. Although the ETS1 might be important for the regulation of some mtp53 target genes [160], side-by-side comparison using recombinant proteins revealed that mtp53 preferentially associates with ETS2 [44,158]. All structural and DNA contact p53 mutants bound to ETS2 [44, 158,162]. Whereas ETS1 knockdown had no effect on mtp53 target gene expression, ETS2 depletion reproduced changes in gene expression that occur on mtp53 depletion suggesting close relationship between mtp53 and ETS2. The observation that ETS2 interacts with various mtp53 (R175H, R248Q, R248W, R249S, R273H, R273L, and R280K) suggests that through ETS2 binding, different mtp53 proteins reveal oncogenic potential through common mechanisms consistent with the recent MD Anderson study [172].
The VCU group studied the mechanism for mtp53 binding by mapping the human genomic binding sites for p53 R273H (one of GOF mtp53) using ChIP-seq and showed that the protein was localized to ETS DNA sequence motifs with ETS1 and GABPA binding, both within promoters and distal to promoters [160]. p53 R273H showed significant and substantial binding to bidirectional promoters, which were enriched for inverted repeated ETS DNA sequence motifs [160]. p53 R273H showed an exponential increase in probability of binding to promoters with a higher number of ETS motifs [160]. The same group reported that in cells expressing p53 R273H GOF mtp53 simultaneously upregulates genes from multiple signaling pathways by recognizing promoters containing distinct transcription factor binding sites [161]. Thus, inhibition of one GOF mtp53-induced signaling cascade would be insufficient to inhibit tumor growth, but rather global inhibition of GOF mtp53 activity in necessary to fond a novel anti-cancer therapeutic agents [161].
It should be remembered that ETS2 binds to the tetramerization domain of p53 [173][174][175], which is thought to be functionally intact in both WTp53 and mtp53. Then the question is how ETS2 distinguishes between mtp53 and WTp53. One possibility is that p53 mutants adopt a different structure from normal p53 that enables their interaction with ETS2. However, some GOF p53 proteins have similar structures to normal p53 which raises the question for this. The 2 nd possibility is when WTp53 in searching for DNA sequences throughout the genome, it might not be able to interact with ETS2 [175]. When WTp53 is bound to genomic DNA, it might alter the structure in a way that not compatible with binding to ETS2 [175]. The 3 rd possibility is that the expression of some WTp53 target genes prevents the normal protein interactions found in mtp53 [175]. Whatever the scenario is, it is of paramount importance to elucidate the mechanisms of activation/ stabilization of mt53 since it is mutated in 50% of human cancers associated with malignant potential of tumors cells, hence worse prognosis of patients.
Very recently, the Lozano's group elucidated how GOF mtp53 drove cancer metastasis by developing a traceable osteosarcoma mouse model [172]. They showed that mtp53 mice developed osteosarcomas with increased metastasis as compared with p53-null mice. The RNA-seq analysis of tumors identified a cluster of small nucleolar RNAs (snoRNAs) that were highly up-regulated in mtp53 mutant tumors with enrichment of Ets2 transcription factor-binding site [172]. Consistently, homozygous deletion of Ets2 in p53 mutant mice resulted in significant down-regulation of snoRNAs with simultaneous reversion of the pro-metastatic phenotype of tumors induced my mtp53, which had no effect on the growth of primary osteosarcoma. Thus Ets2 inhibition is a potential therapeutic vulnerability in mtp53 mutant osteosarcomas [172].

Future directions
Ets1 shows both oncogenic and tumor suppressive activity dependent on the assay conditions. It is generally considered an oncogene by aberrant overexpression in human cancers. The role of Ets1 in embryonic maintenance or inhibition of cell proliferation for lymphoid cells is clear from gene knockout studies. Accumulating pieces of evidence has suggested that Ets1 accelerates angiogenesis, and has an oncogenic role mediated by MAPK signaling. Conversely, Ets2 has a tumor-suppressive role by upregulation the transcription of p16 INK4a although it stimulates the transcription of Cyclin D1. The situation is completely reversed when the cells have mutant p53; ETS2 reveals oncogenic function by stabilizing mutant p53 as evidenced by the recent study employing gene engineered mice [172]. The authors concluded that blocking Ets2 activity is essential to prevent lung metastasis of osteosarcoma. Thus the search for ETS2 blocker is of paramount importance to prevent cancer metastasis. Both ETS1 and ETS2 stimulate p53; however, neither ETS1 nor ETS2 is in the list of target genes for p53 [176,177]. Currently, the role of other ETS family proteins on activation/inhibition of mutant p53 is unknown. Thus extensive studies should be done in this direction since p53 is mutated in half of human cancers with GOF functions and that ETS have so many other family members.
It is very intriguing to know that human telomerase promoter have novel ETS sites when they are mutated [11]. That may be the reason why many human cancers have increased telomerase activity with long telomeres where the inhibitors are in clinical trials to cancer. Since human TERT promoter has both E2F1 and WT1 binding sites, it will be important how these transcription factors regulate the hTERT promoter. It will be also essential to analyze which ETS proteins bind to the hTERT promoter to translate the findings of ETS mutation to clinical levels.